Using the conditional and tamoxifen-inducible sATF6 knock-in mouse line sATF6-MER that was developed by our group, we previously showed that ATF6 activation in neurons provided acute beneficial effects after transient ischemic stroke (Yu et al., 2017), supporting the notion that the ATF6 pathway is a potential therapeutic target in stroke. The gene discussed is ATF6; the disease is stroke disorder.